News

FDA extends review of Exelixis' zanzalintinib combo for colorectal cancer, decision due March 2027

What happened? On 11 September 2026, Exelixis disclosed in a Securities and Exchange Commission filing that the US Food and Drug Administration has extended its review of the company's application for zanzalintinib, its next-generation oral cancer medicine, taken in combination with Tecentriq (atezolizumab) from Roche for metastatic colorectal cancer — cancer of the colon or rectum that has spread to other parts of the body. The agency asked for the extension while it awaits updated safety and efficacy data from the company, pushing the decision deadline from 3 December 2026 to 3 March 2027.

Why it matters: Zanzalintinib is Exelixis' planned successor to Cabometyx, the franchise drug that still generates the bulk of its revenue, so the review's timing matters for both patients and the company's growth outlook. The application had already been on uncertain ground: in June 2026, zanzalintinib missed one of the primary endpoints — a predefined measure of success — measuring overall survival in a subpopulation of patients in a Phase 3 study of metastatic colorectal cancer. Analysts at Leerink Partners and William Blair argued at the time that approval was still likely in third-line disease, because the trial did meet its other primary endpoint of overall survival in all participants regardless of liver-metastasis status, and the drug had previously beaten Bayer's standard-of-care drug Stivarga head-to-head in a Phase 3 trial. The extension defers the revenue inflection at least another quarter, and the FDA's request for updated data signals the agency wants fuller evidence before deciding.

Read more: Fierce Biotech, 11 September 2026 · Exelixis SEC filing, 11 September 2026

More top stories